These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38543755)

  • 21. Outcomes of the CT2 study: A 'one-stop-shop' for community-based hepatitis C testing and treatment in Yangon, Myanmar.
    Draper BL; Htay H; Pedrana A; Yee WL; Howell J; Pyone Kyi K; Naing W; Sanda Aung K; Markby J; Easterbrook P; Bowring A; Aung W; Sein YY; Nwe N; Myint KT; Shilton S; Hellard M
    Liver Int; 2021 Nov; 41(11):2578-2589. PubMed ID: 34153155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The rate of hepatitis C reinfection in Canadians coinfected with HIV and its implications for national elimination.
    Young J; Wang S; Lanièce Delaunay C; Cooper CL; Cox J; Gill MJ; Hull M; Walmsley S; Wong A; Klein MB;
    Int J Drug Policy; 2023 Apr; 114():103981. PubMed ID: 36893502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C care cascade in a large academic healthcare system, 2012 to 2018.
    Nakayama J; Hertzberg VS; Ho JC; Simpson RL; Cartwright EJ
    Medicine (Baltimore); 2023 Mar; 102(10):e32859. PubMed ID: 36897716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.
    Socías ME; Ti L; Wood E; Nosova E; Hull M; Hayashi K; Debeck K; Milloy MJ
    Liver Int; 2019 Aug; 39(8):1400-1407. PubMed ID: 30653809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
    Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
    Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
    Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
    Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-care.
    Valencia J; Lazarus JV; Ceballos FC; Troya J; Cuevas G; Resino S; Torres-Macho J; Ryan P
    Liver Int; 2022 Feb; 42(2):309-319. PubMed ID: 34767680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019.
    Requena MB; Protopopescu C; Stewart AC; van Santen DK; Klein MB; Jarrin I; Berenguer J; Wittkop L; Salmon D; Rauch A; Prins M; van der Valk M; Sacks-Davis R; Hellard ME; Carrieri P; Lacombe K;
    Int J Drug Policy; 2024 Feb; 124():104311. PubMed ID: 38184902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada.
    Nouch S; Gallagher L; Erickson M; Elbaharia R; Zhang W; Wang L; Bacani N; Kason D; Kleban H; Knebel L; Hall D; Barrios R; Hull M
    Int J Drug Policy; 2018 Sep; 59():76-84. PubMed ID: 30048877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington.
    Corcorran MA; Tsui JI; Scott JD; Dombrowski JC; Glick SN
    Drug Alcohol Depend; 2021 Mar; 220():108525. PubMed ID: 33461152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 'Not just one box that you tick off' - Deconstructing the hepatitis C care cascade in the interferon-free direct acting antiviral era from the client perspective.
    Marshall AD; Rance J; Grebely J; Treloar C
    Int J Drug Policy; 2022 Apr; 102():103610. PubMed ID: 35151085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system.
    Gibbs D; Price O; Grebely J; Larney S; Sutherland R; Read P; Butler K; Degenhardt L; Peacock A
    Drug Alcohol Depend; 2021 Nov; 228():109050. PubMed ID: 34607193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment.
    Seaman A; King CA; Kaser T; Geduldig A; Ronan W; Cook R; Chan B; Levander XA; Priest KC; Korthuis PT
    Int J Drug Policy; 2021 Oct; 96():103359. PubMed ID: 34325969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Equity Health; 2021 Mar; 20(1):81. PubMed ID: 33740984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress of Hepatitis C elimination in Viennese people living with HIV after two decades of increasing cure rates.
    Chromy D; Bauer D; Simbrunner B; Jachs M; Hartl L; Schwabl P; Binter T; Steininger L; Schwarz C; Rieger A; Grabmeier-Pfistershammer K; Trauner M; Ferenci P; Peck-Radosavljevic M; Mandorfer M; Reiberger T
    Infect Dis (Lond); 2023 Mar; 55(3):189-198. PubMed ID: 36484317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
    Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
    J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges in hepatitis C elimination despite highly effective antiviral agents in patients with and without intravenous drug use.
    Bota S; Razpotnik M; Hucke F; Urak C; Flatscher K; Peck-Radosavljevic M
    Wien Klin Wochenschr; 2021 Jul; 133(13-14):641-646. PubMed ID: 34032930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved Hepatitis C Cure Cascade Outcomes Among Urban Baby Boomers in the Direct-Acting Antiviral Era.
    Dupont SC; Fluker SA; Quairoli KM; Body C; Okosun I; Lom J; Miller LS
    Public Health Rep; 2020 Jan; 135(1):107-113. PubMed ID: 31756116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia.
    Yousafzai MT; Alavi M; Valerio H; Hajarizadeh B; Grebely J; Dore GJ
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study.
    Malme KB; Ulstein K; Finbråten AK; Wüsthoff LEC; Kielland KB; Hauge J; Dalgard O; Midgard H
    Int J Drug Policy; 2023 Jun; 116():104044. PubMed ID: 37149914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.